Aseptic loosening

Gene Therapy

Volumn 11, Issue 4, 2004, Pages 402-407

  Wooley, P H ^a   Schwarz, E M ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Bone; Inflammation; Osteoclast; Osteolysis; Prosthesis

Indexed keywords

ADENOVIRUS VECTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; CALCIUM BONE LEVEL; CELL DIFFERENTIATION; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HUMAN; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS LOOSENING; RAT; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; JOINT PROSTHESIS; OSTEOLYSIS; PROSTHESIS FAILURE;

EID: 1342327556     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302202     Document Type: Review

References (89)

1. Glassman AH, Engh CA, Suthers KE. Ten year follow-up of total hip arthroplasty using extensively porous coated femoral components. Orthop Trans 1993; 16: 702.
2. Kim YH, Kim VE. Results of the Harris-Galante hip prosthesis. Orthrop Trans 1993; 16: 701-702.
3. Stauffer RN. Correction of arthritic deformities of the hip. In: McCarty DJ (ed). Arthritis & Allied Conditions. Philadephia: Lea & Febinger, 1985, pp 757-770.
4. Mulroy WF, Harris WH. Revision total hip arthroplasty with use of so-called second-generation cementing techniques for aseptic loosening of the femoral component. A fifteen-year-average follow-up study. J Bone Joint Surg Am 1996; 78: 325-330.
5. Jasty MJ et al. Localized osteolysis in stable, non-septic total hip replacement. J Bone Joint Surg Am 1986; 68: 912-919.
6. Imkamp E, Mittermayer C, Hunold W. Animal experiment studies of the biocompatibility of colored and plain lens haptics of polymethylmethacrylate. Fortschritte Ophthalmol 1990; 87: 95-98.
7. Boss JH, Shajrawi I, Mendes DG. The nature of the bone-implant interface. The lessons learned from implant retrieval and analysis in man and experimental animal. Med Progr Technol 1994; 20: 119-142.
8. Maguire Jr JK, Coscia MF, Lynch MH. Foreign body reaction to polymeric debris following total hip arthroplasty. Clin Orthop Relat Res 1987; 216: 213-223.
9. Perry MJ et al. Analysis of cell types and mediator production from tissues around loosening joint implants. Br J Rheumatol 1995; 34: 1127-1134.
10. Boynton EL, Henry M, Morton J, Waddell JP. The inflammatory response to particulate wear debris in total hip arthroplasty. Can J Surg 1995; 38: 507-515.
11. Santavirta S et al. Aggressive granulomatous lesions associated with hip arthroplasty. Immunopathological studies. J Bone Joint Surg Am 1990; 72: 252-258.
12. Eftekhar NS, Doty SB, Johnston AD, Parisien MV. Prosthetic synovitis. Hip 1985: 169-183.
13. Kaufman RL, Tong I, Beardmore TD. Prosthetic synovitis: clinical and histologic characteristics. J Rheumatol 1985; 12: 1066-1074.
14. Thornhill TS et al. Biochemical and histological evaluation of the synovial-like tissue around failed (loose) total joint replacement prostheses in human subjects and a canine model. Biomaterials 1990; 11: 69-72.
15. Manolagas SC et al. Estrogen, cytokines, and the control of osteoclast formation and bone resorption in vitro and in vivo. Osteoporosis Int 1993; 3(Suppl 1): 114-116.
16. Bertolini D et al. Stimulation of bone resorption and inhibition of bone formation in vitro by tumor necrosis factors. Nature 1986; 319: 516-518.
17. Gowen M et al. An interleukin 1-like factor stimulates bone resorption in vitro. Nature 1983; 306: 378.
18. Lassus J et al. Macrophage activation results in bone resorption. Clin Orthop 1998; 352: 7-15.
19. Xu JW et al. Interleukin-11 (IL-11) in aseptic loosening of total hip replacement (THR). Scand J Rheumatol 1998; 27: 363-367.
20. Xu JW et al. Production of platelet-derived growth factor in aseptic loosening of total hip replacement. Rheumatol Int 1998; 17: 215-221.
21. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992; 4: 754-759.
22. Bando Y et al. Immunocytochemical localization of inflammatory cytokines and vascular adhesion receptors in radicular cysts. J Oral Pathol Med 1993; 22: 221-227.
23. Pollice PE, Silverton SF, Horowitz SM. Polymethylmethacrylate-stimulated macrophages increase rat osteoclast precursor recruitment through their effect on osteoblasts in vitro. J Orthop Res 1995; 13: 325-334.
24. Han CD, Choe WS, Yoo JH. Effect of polyethylene wear on osteolysis in cementless primary total hip arthroplasty: minimal 5-year follow-up study. J Arthroplasty 1999; 14: 714-723.
25. Sacomen D et al. Effects of polyethylene particles on tissue surrounding knee arthroplasties in rabbits. J Biomed Mater Res 1998; 43: 123-130.
26. Sabokbar A, Pandey R, Quinn JM, Athanasou NA. Osteoclastic differentiation by mononuclear phagocytes containing biomaterial particles. Arch Orthop Trauma Surg 1998; 117: 136-140.
27. Wang W et al. Biomaterial particle phagocytosis by bone-resorbing osteoclasts. J Bone Joint Surg Br 1997; 79: 849-856.
28. Xu JW et al. Macrophage-colony stimulating factor (M-CSF) is increased in the synovial-like membrane of the periprosthetic tissues in the aseptic loosening of total hip replacement (THR). Clin Rheumatol 1997; 16: 243-248.
29. Rader CP et al. Cytokine response of human macrophage-like cells after contact with polyethylene and pure titanium particles. J Arthroplasty 1999; 14: 840-848.
30. Al-Saffar N, Khwaja HA, Kadoya Y, Revell PA. Assessment of the role of GM-CSF in the cellular transformation and the development of erosive lesions around orthopaedic implants. Am J Clin Pathol 1996; 105: 628-639.
31. Shanbhag AS et al. Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasty. J Arthroplasty 1995; 10: 498-506.
32. Appel AM et al. Prosthesis-associated pseudomembrane-induced bone resorption. Br J Rheumatol 1990; 29: 32-36.
33. Shanbhag AS, Macaulay W, Stefanovic-Racic M, Rubash HE. Nitric oxide release by macrophages in response to particulate wear debris. J Biomed Mater Res 1998; 41: 497-503.
34. Horowitz SM, Luchetti WT, Gonzales JB, Ritchie CK. The effects of cobalt chromium upon macrophages. J Biomed Mater Res 1998; 41: 468-473.
35. Granchi D et al. Bone-resorbing cytokines in serum of patients with aseptic loosening of hip prostheses. J Bone Joint Surg Br 1998; 80: 912-917.
36. Manlapaz M, Maloney WJ, Smith RL. In vitro activation of human fibroblasts by retrieved titanium alloy wear debris. J Orthop Res 1996; 14: 465-472.
37. Wang JY, Wicklund BH, Gustilo RB, Tsukayama DT. Titanium, chromium and cobalt ions modulate the release of bone-associated cytokines by human monocytes/macrophages in vitro. Biomaterials 1996; 17: 2233-2240.
38. Glant TT, Jacobs JJ. Response of three murine macrophage populations to particulate debris: bone resorption in organ cultures. J Orthop Res 1994; 12: 720-731.
39. Maloney WJ et al. Isolation and characterization of wear particles generated in patients who have had failure of a hip arthroplasty without cement. J Bone Joint Surg Am 1995; 77: 1301-1310.
40. Anderson DM et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-179.
41. Roux S, Orcel P. Bone loss: factors that regulate osteoclast differentiation: an update. Arthritis Res 2000; 2: 451-456.
42. Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 1999; 141: 195-210.
43. Simonet WS et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
44. Lacey DL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
45. Yasuda H et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-3602.
46. Kong YY et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309.
47. Bucay N et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268.
48. Nakagawa N et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998; 253: 395-400.
49. Myers DE et al. Expression of functional RANK on mature rat and human osteoclasts. FEBS Lett 1999; 463: 295-300.
50. Hsu H et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96: 3540-3545.
51. Dougall WC et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13: 2412-2424.
52. Li J et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000; 97: 1566-1571.
53. Teitelbaum SL. Osteoclasts, integrins, and osteoporosis. J Bone Miner Metab 2000; 18: 344-349.
54. Capparelli C et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000; 60: 783-787.
55. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
56. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
57. Finco TS, Baldwin AS. Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Immunity 1995; 3: 263-272.
58. Iotsova V et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997; 3: 1285-1289.
59. Franzoso G et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997; 11: 3482-3496.
60. Unlap MT, Jope RS. Dexamethasone attenuates NF-kappa B DNA binding activity without inducing I kappa B levels in rat brain in vivo. Brain Res Mol Brain Res 1997; 45: 83-89.
61. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin Jr AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-286.
62. Howie DW, Vernon-Roberts B, Oakeshott R, Manthey B. A rat model of resorption of bone at the cement-bone interface in the presence of polyethylene wear particles. J Bone Joint Surg Am 1988; 70: 257-263.
63. Shanbhag AS, Hasselman CT, Rubash HE. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop 1997; 344: 33-43.
64. Pap G et al. Development and characteristics of a synovial-like interface membrane around cemented tibial hemiarthroplasties in a novel rat model of aseptic prosthesis loosening. Arthritis Rheum 2001; 44: 956-963.
65. Sud S et al. Effects of cytokine gene therapy on particulate-induced inflammation in the murine air pouch. Inflammation 2001; 25: 361-372.
66. Schwarz EM et al. Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. J Orthop Res 2000; 18: 849-855.
67. Merkel KD et al. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999; 154: 203-210.
68. Schwarz EM et al. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis. J Orthop Res 2000; 18: 472-480.
69. Childs LM et al. In vivo RANK signaling blockade using the receptor activator of NF-kappa B:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 2002; 17: 192-199.
70. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res 2001; 16: 338-347.
71. Haynes DR et al. Drug inhibition of the macrophage response to metal wear particles in vitro. Clin Orthop Relat Res 1996; 323: 316-326.
72. Thompson RC, Dripps DJ, Eisenberg SP. Interleukin-1 receptor antagonist (IL-1ra) as a probe and as a treatment for IL-1 mediated disease. Int J Immunopharmacol 1992; 14: 475-480.
73. Wooley PH et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993; 36: 1305-1314.
74. van Roon JA et al. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996; 39: 829-835.
75. Perretti M, Szabo C, Thiemermann C. Effect of interleukin-4 and interleukin-10 on leucocyte migration and nitric oxide production in the mouse. Br J Pharmacol 1995; 116: 2251-2257.
76. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Therapy 1994; 1: 136-138.
77. Hung GL et al. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Therapy 1994; 1: 64-69.
78. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Effect of antitumor necrosis factor-alpha gene therapy on wear debris-induced osteolysis. J Bone Joint Surg Am 2001; 83A: 1789-1797.
79. Carmody EE et al. Viral interleukin-10 gene inhibition of inflammation, osteoclastogenesis, and bone resorption in response to titanium particles. Arthritis Rheum 2002; 46: 1298-1308.
80. Yang SY et al. IL-10 and IL-1ra gene transfer using retroviral vectors ameliorates an experimental inflammatory reaction to orthopaedic wear debris. Inflamm Res 2002; 51: 342-350.
81. Joosten LA et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049-5055.
82. Assuma R et al. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1998; 160: 403-409.
83. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech 2000; 50: 229-235.
84. Tani-Ishii N, Tsunoda A, Teranaka T, Umemoto T. Autocrine regulation of osteoclast formation and bone resorption by IL-1 alpha and TNF alpha. J Dent Res 1999; 78: 1617-1623.
85. Lam J et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-1488.
86. Zhang YH et al. Tumor necrosis factor-alpha stimulates RANKL-induced osteoclastogenesis via coupling of TNFr1 and RANK signaling pathways. J Biol Chem 2001; 276: 563-568.
87. Yang SY et al. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum 2002; 46: 2514-2523.
88. Goater JJ et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res 2002; 20: 169-173.
89. Ulrich-Vinther M et al. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am 2002; 84A: 1405-1412.